Billiontoone (NASDAQ:BLLN) SVP Sells $131,582.62 in Stock

Billiontoone, Inc. (NASDAQ:BLLN) SVP Bosch John Roderick Ten sold 1,417 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $92.86, for a total transaction of $131,582.62. Following the transaction, the senior vice president owned 27,884 shares in the company, valued at approximately $2,589,308.24. The trade was a 4.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bosch John Roderick Ten also recently made the following trade(s):

• On Monday, June 29th, Bosch John Roderick Ten sold 1,416 shares of Billiontoone stock. The shares were sold at an average price of $120.00, for a total transaction of $169,920.00.
• On Monday, June 15th, Bosch John Roderick Ten sold 2,832 shares of Billiontoone stock. The stock was sold at an average price of $101.47, for a total value of $287,363.04.

Billiontoone Trading Down 0.8%

Billiontoone stock opened at $93.33 on Friday. The business has a 50 day moving average price of $116.41 and a two-hundred day moving average price of $94.59. The company has a quick ratio of 11.31, a current ratio of 11.69 and a debt-to-equity ratio of 0.17. Billiontoone, Inc. has a 12 month low of $61.96 and a 12 month high of $150.44. The stock has a market cap of $4.40 billion and a price-to-earnings ratio of 133.33.

Billiontoone (NASDAQ:BLLN) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.15 earnings per share for the quarter, hitting the consensus estimate of $0.15. The company had revenue of $109.45 million for the quarter. Billiontoone had a return on equity of 9.96% and a net margin of 8.04%. As a group, equities analysts forecast that Billiontoone, Inc. will post 0.83 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. JPMorgan Chase & Co. decreased their target price on shares of Billiontoone from $145.00 to $130.00 and set an “overweight” rating on the stock in a research report on Thursday, August 6th. BTIG Research cut their price target on shares of Billiontoone from $142.00 to $130.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Wall Street Zen downgraded Billiontoone from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Guggenheim initiated coverage on Billiontoone in a research note on Monday, June 29th. They issued a “buy” rating and a $125.00 price objective on the stock. Finally, Weiss Ratings raised Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, June 23rd. Six equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Billiontoone has an average rating of “Moderate Buy” and an average target price of $126.71.

Hedge Funds Weigh In On Billiontoone

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BLLN. Rossby Financial LCC bought a new stake in Billiontoone during the fourth quarter worth about $25,000. Wells Fargo & Company MN bought a new position in shares of Billiontoone in the fourth quarter valued at approximately $76,000. Smartleaf Asset Management LLC bought a new position in shares of Billiontoone in the fourth quarter valued at approximately $80,000. Nano Cap New Millennium Growth Fund L P acquired a new position in shares of Billiontoone in the 4th quarter worth approximately $82,000. Finally, Renaissance Capital LLC acquired a new position in shares of Billiontoone in the 4th quarter worth approximately $201,000.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.